Company: PFSA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001013762-25-004396
Chunk: 859

Company: Profusa, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 5
Chunk 859
---
 Mr. O’Rourke
also served in both the U.S. Navy and Air Force. Mr. O’Rourke served as Director for AXIM Biotechnologies from July 2020 to present.
AXIM is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological
conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. Mr. O’Rourke received a Bachelor of Arts in Political Science
from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United
States Air Force’s Institute of Technology. We believe that Mr. O’Rourke is well-qualified to serve as a director of our company
based on Mr. O’Rourke’s leadership and consulting experience in the healthcare industry.

51

Ed Johnson - Director 

Ed Johnson has served as a
director since the effective date of our initial public offering. Since March 2020, Mr. Johnson has served as the chief executive officer
of iONEBIOUSA Molecular COVID-19 Technologies, which he founded. Since March 2018, Mr. Johnson has served as chief executive officer of
Johnson Global Ventures, LLC. Since March 2018, Mr. Johnson has served on the Advisory Board to Advantage Capital Partners. Mr. Johnson
received a Bachelor of Science in Marketing from Florida State University and a M.B.A. from Nova Southeastern University. We believe that
Mr. Johnson is well-qualified to serve as a director of our company based on Mr. Johnson’s healthcare focused experience.

Lauren Chung - Director 

Lauren Chung has served as
a director since the effective date of our initial public offering. Since November 2019, Dr. Chung has served as chief executive officer
of MINLEIGH LLC, identifying, evaluating and partnering with companies for investments and strategic, operational, and commercial opportunities,
and venture partner at Yozma Group. From May 2017 to November 2019, Dr. Chung was an Equity Research Managing Director at WestPark Capital.
From August 2016 to April 2017, Dr. Chung as in equity research at Maxim Group. Previously, Dr. Chung founded and served as chief operating
officer and chief compliance officer of Tokum Capital Management, a global healthcare investment fund. Prior to that, she managed healthcare
investment portfolios at institutional investment firms. Dr. Chung serves as director of Todos Medical Ltd. Dr. Chung previously served
as director of Cure Pharmaceutical